REFERENCES
  1. Luca S, Mihaescu T. History of BCG Vaccine. Maedica (Bucur) 2013;8:53-8.
  2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
  3. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):S86-90.
  4. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013;104:22-7.
  5. Koch GE, Smelser WW, Chang SS. Side effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How To Manage Them. J Urol 2021;149:11-20.
  6. Abu-Nader R, Terrell CL. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clinic Proceedings 2002;77:393-7.
  7. Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Tejido Á, San Juan R, et al . Bacillus Calmette- Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer. Medicine 2014;93:236-54.